Best Practices of 18F-Fluciclovine PET/CT Imaging for Recurrent Prostate Cancer: A Guide for Technologists

(18)F-fluciclovine is a Food and Drug Administration-approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. (18)F-fluciclovine PET/CT is performed significantly differently from (18)F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the (18)F-fluciclovine PET/CT protocol.